Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 7/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | GGT1 | P19440 | 4/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.44 |
| ▸ | GSR | P00390 | 2/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.43 |
| ▸ | GRIK3 | Q13003 | 4/20 | 0.43 |
| ▸ | GRIK5 | Q16478 | 4/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564563 | 1.00 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL3145928 | 1.00 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL2474141 | 0.83 | SLC7A5 (0.54) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL29148903 | 0.83 | SLC7A5 (0.54) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL10618897 | 0.81 | PTGS1 (0.55) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL6832737 | 0.81 | PTGS1 (0.55) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL5296510 | 0.80 | GRIK1 (0.46) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL6831240 | 0.80 | GRIK1 (0.46) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| Aspartic Acid SCHEMBL7717425 | 0.79 | GLRA1 (0.53) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| Aspartic Acid SCHEMBL307008 | 0.79 | GLRA1 (0.53) | GRIK1GRIK2GRM1GRM2SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107903337-A | A kind of chitosan derivatives with mucosa-adherent and Pept-1 targetings and preparation method thereof | 中国药科大学 | 2018-04-13 | — | — | CN | claimed |
| US-7767826-B2 | Process for the synthesis of L-(+)-ergothioneine | PHARMATECH INTERNATIONAL, INC. (US) | 2010-08-03 | — | — | US | claimed |
| US-20090093642-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | PHARMATECH INTERNATIONAL, INC. | 2009-04-09 | — | — | US | claimed |
| WO-2009045413-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | PHARMATECH INTERNATIONAL, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-0980366-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | claimed |
| CN-107903337-A | A kind of chitosan derivatives with mucosa-adherent and Pept-1 targetings and preparation method thereof | 中国药科大学 | 2018-04-13 | — | — | CN | disclosed |
| US-9603943-B2 | Polyesteramide platform for site specific drug delivery | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150290336-A1 | POLYESTERAMIDE PLATFORM FOR SITE SPECIFIC DRUG DELIVERY | ABBOTT CARDIOVASCULAR SYSTEMS (US) | 2015-10-15 | — | — | US | disclosed |
| US-9095619-B2 | Polyesteramide platform for site specific drug delivery | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150010491-A1 | POLYESTERAMIDE PLATFORM FOR SITE SPECIFIC DRUG DELIVERY | ABBOTT CARDIOVASCULAR SYSTEMS (US) | 2015-01-08 | — | — | US | disclosed |
| US-8865148-B2 | Polyesteramide platform for site specific drug delivery | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140120053-A1 | POLYESTERAMIDE PLATFORM FOR SITE SPECIFIC DRUG DELIVERY | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20090093642-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | PHARMATECH INTERNATIONAL, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2009045413-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | PHARMATECH INTERNATIONAL, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| EP-1952830-A1 | Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same | Abbott Cardiovascular Systems, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1694373-B1 | BIOLOGICALLY ABSORBABLE COATINGS FOR IMPLANTABLE DEVICES BASED ON POLY(ESTER AMIDES) AND METHODS FOR FABRICATING THE SAME | ABBOTT CARDIOVASCULAR SYSTEMS (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070249801-A1 | Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same | ADVANCED CARDIOVASCULAR SYSTEMS, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070243256-A1 | Polyesteramide platform for site specific drug delivery | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2007-10-18 | — | — | US | disclosed |
| US-7220816-B2 | Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20050131201-A1 | Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same | ADVANCED CARDIOVASCULAR SYSTEMS, INC. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070243256-A1 | Polyesteramide platform for site specific drug delivery | CES2, KIT, NAAA | GRIK1 2902/4885GRIK2 2115/4885GRM1 4457/4885 |
| US-20140120053-A1 | POLYESTERAMIDE PLATFORM FOR SITE SPECIFIC DRUG DELIVERY | CES2, KIT, NAAA | GRIK1 2902/4885GRIK2 2115/4885GRM1 4457/4885 |
| US-20150010491-A1 | POLYESTERAMIDE PLATFORM FOR SITE SPECIFIC DRUG DELIVERY | CES2, KIT, NAAA | GRIK1 2902/4885GRIK2 2115/4885GRM1 4457/4885 |
| US-20150290336-A1 | POLYESTERAMIDE PLATFORM FOR SITE SPECIFIC DRUG DELIVERY | CES2, KIT, NAAA | GRIK1 2902/4885GRIK2 2115/4885GRM1 4457/4885 |
| US-20090093642-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | TTPA, DTYMK, TST | GRIK1 974/4885GRIK2 884/4885GRM1 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.